Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease

被引:107
|
作者
Morton, AJ
Faull, RLM
Edwardson, JM
机构
[1] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England
[2] Univ Auckland, Fac Med & Hlth Sci, Dept Anat, Auckland 1, New Zealand
基金
英国惠康基金;
关键词
Huntington's disease; complexin II; striosome; matrix; SNARE; human; neurodegeneration;
D O I
10.1016/S0361-9230(01)00611-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have recently described the progressive and selective loss of the presynaptic protein complexin II in brains of mice (R6/2) transgenic for the Huntington's disease (HD) mutation. Here we have determined the expression of components of the synaptic vesicle fusion machinery in the striatum and hippocampus from post-mortem brains of HD cases and neurologically normal controls. As in the brains of R6/2 mice, complexin II was markedly depleted in the HD striatum; the depletion was compartmentally organized, with complexin II-poor regions corresponding with areas of low immunoreactivity toward the matrix marker calbindin D-28K. Decreases in the levels of the soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) protein synaptobrevin 2 and of rab3A were also seen, but none of the other proteins tested was significantly affected. In the hippocampus, levels of complexin II, synaptobrevin 2, rab3A, and also of alpha -SNAP, were markedly elevated in HD brains. We suggest that the observed abnormalities in the expression of proteins known to be involved in the control of neurotransmitter release, including both modulators and core components of the vesicle fusion machinery, might account for at least some of the functional abnormalities seen in HD. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 50 条
  • [41] Endosomal vesicle fusion machinery is involved with the contractile vacuole in Dictyostelium discoideum
    Manna, Paul T.
    Barlow, Lael D.
    Ramirez-Macias, Inmaculada
    Herman, Emily K.
    Dacks, Joel B.
    JOURNAL OF CELL SCIENCE, 2023, 136 (02)
  • [42] Alpha-theta border EEG abnormalities in preclinical Huntington's disease
    Ponomareva, Natalya
    Klyushnikov, Sergey
    Abramycheva, Natalya
    Malina, Dania
    Scheglova, Nadejda
    Fokin, Vitaly
    Ivanova-Smolenskaia, Irina
    Illarioshldn, Sergey
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2014, 344 (1-2) : 114 - 120
  • [43] Pathomechanisms of behavioral abnormalities in Huntington disease: an update
    Jellinger, Kurt A.
    JOURNAL OF NEURAL TRANSMISSION, 2024, 131 (09) : 999 - 1012
  • [44] Huntington's disease-like 2: a clinical, pathological, and molecular comparison to Huntington's disease
    Margolis, RL
    Holmes, SE
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 187 - 196
  • [45] Calpain activation in Huntington's disease
    Gafni, J
    Ellerby, LM
    JOURNAL OF NEUROSCIENCE, 2002, 22 (12) : 4842 - 4849
  • [46] Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity
    Morigaki, Ryoma
    Goto, Satoshi
    BRAIN SCIENCES, 2017, 7 (06): : 02 - 25
  • [47] Iron dysregulation in Huntington's disease
    Muller, Michelle
    Leavitt, Blair R.
    JOURNAL OF NEUROCHEMISTRY, 2014, 130 (03) : 328 - 350
  • [48] DNA Methylation in Huntington's Disease
    Zsindely, Nora
    Siagi, Fruzsina
    Bodai, Laszlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [49] Huntington's disease, calcium, and mitochondria
    Giacomello, Marta
    Hudec, Roman
    Lopreiato, Raffaele
    BIOFACTORS, 2011, 37 (03) : 206 - 218
  • [50] Huntington's disease: A bimolecular vision
    Leite, JF
    REVISTA DE NEUROLOGIA, 2001, 32 (08) : 762 - 767